Cantargia: New positive interim results on nadunolimab combination therapy in NSCLC published in abstract for the annual ESMO Congress
Cantargia AB today announced the publication of an abstract disclosing novel clinical interim data from the CANFOUR study. The abstract was submitted in May 2021 for the upcoming ESMO Congress starting 16 September, 2021. In 15 non-small cell lung cancer (NSCLC) patients evaluated for efficacy, nadunolimab (CAN04) combined with gemcitabine/cisplatin showed an overall response rate (ORR) of 60%, a median duration of response (DOR) of 6.2 months and a median progression-free survival (PFS) of 8.2 months. All these efficacy parameters compare favorably to historical control data from gemcitabine/
Meetings: A waste of time, or an opportunity to share and refine information while strengthening a sense of community? This catch 22 has led employees to question the logic of meetings, which now consume most of the workday.The global transition from office to remote work has significantly increased the number of online meetings. For Kiiltonians, this new way of life has challenged the old ways of time management, especially when scheduling and attending back-to-back digital meetings without interrupting the natural flow of everyday work. Aware of this growing pain point, Kiilto wanted to